Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®

29 March 2022 | Tuesday | News


Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the United Kingdom (U.K.) and the Republic of Ireland.
Image Source : Public Domain

Image Source : Public Domain

Under the terms of the agreement, Xiel, a specialist distributor of Nuclear Medicine, Radiotherapy and Diagnostic Radiology technologies across the U.K. and Ireland will be the exclusive commercial distributor of Illuccix in the U.K. (a top 5 European market by GDP) and the Republic of Ireland for a period of three years from the national approval date.

Xiel Managing Director, Jack Knight stated, "PSMA PET imaging is emerging as the standard of care having recently been included in European1 and U.S.2,3 clinical practice guidelines. We are delighted to be adding Illuccix® to our nuclear medicine portfolio and look forward to bringing this product to British and Irish men in need, upon regulatory approval. This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 61,000 men diagnosed with prostate cancer each year in the U.K. and the Republic of Ireland." 

Telix CEO EMEA, Richard Valeix added, "The U.K. and Republic of Ireland are one of Telix's largest potential markets within the EMEA region, so we are pleased to have secured this agreement in anticipation of regulatory approval. Telix is creating a network of leading distribution partners to ensure we have a strong footprint to optimise our service to customer sites and ensure we can bring our imaging agent to patients across the region."

Xiel replaces Curium as Telix's exclusive distribution partner in the U.K. and the Republic of Ireland.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close